Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APOE -by-sex interactions on brain structure and metabolism in healthy elderly controls

  • Sampedro, Frederic|||0000-0002-3933-1355
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • de Leon, Mony J..
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Antón-Aguirre, Sofía
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Camacho, Valle|||0000-0003-0748-0847
  • Falcon, Carles
  • Pavía, Javier
  • Ros, Domènec
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
The APOE effect on Alzheimer Disease (AD) risk is stronger in women than in men but its mechanisms have not been established. We assessed the APOE -by-sex interaction on core CSF biomarkers, brain metabolism and structure in healthy elderly control individuals (HC). Cross-sectional study. HC from the Alzheimer's Disease Neuroimaging Initiative with available CSF (n = 274) and/or 3T-MRI (n = 168) and/or a FDG-PET analyses (n = 328) were selected. CSF amyloid-β (Aβ), total-tau (t-tau) and phospho-tau (p-tau) levels were measured by Luminex assays. We analyzed the APOE -by-sex interaction on the CSF biomarkers in an analysis of covariance (ANCOVA). FDG uptake was analyzed by SPM8 and cortical thickness (CTh) was measured by FreeSurfer. FDG and CTh difference maps were derived from interaction and group analyses. APOE4 carriers had lower CSF Aβ and higher CSF p-tau values than non-carriers, but there was no APOE -by-sex interaction on CSF biomarkers. The APOE -by-sex interaction on brain metabolism and brain structure was significant. Sex stratification showed that female APOE4 carriers presented widespread brain hypometabolism and cortical thinning compared to female non-carriers whereas male APOE4 carriers showed only a small cluster of hypometabolism and regions of cortical thickening compared to male non-carriers. The impact of APOE4 on brain metabolism and structure is modified by sex. Female APOE4 carriers show greater hypometabolism and atrophy than male carriers. This APOE -by-sex interaction should be considered in clinical trials in preclinical AD where APOE4 status is a selection criterion.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease

  • Dekker, Alain D.|||0000-0001-8771-218X
  • Vermeiren, Yannick|||0000-0002-2091-5326
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Aerts, Tony
  • Van Dam, Debby
  • Fernández, Susana|||0000-0002-9777-1156
  • Lleó, Alberto|||0000-0002-2568-5478
  • Videla, Sebastián|||0000-0001-5049-1379
  • Sieben, Anne|||0000-0003-1278-6605
  • Martin, Jean-Jacques
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • De Deyn, Peter Paul|||0000-0002-2228-2964
People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Noradrenaline, adrenaline, and their metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG); dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid; and serotonin and its metabolite 5-hydroxyindoleacetic acid were quantified in 15 brain regions of DS without AD (DS, n = 4), DS with AD (DS+AD, n = 17), early-onset AD (EOAD, n = 11) patients, and healthy non-DS controls (n = 10) in the general population. Moreover, monoaminergic concentrations were determined in cerebrospinal fluid (CSF)/plasma samples of DS (n = 37/149), DS with prodromal AD (DS+pAD, n = 13/36), and DS+AD (n = 18/40). In brain, noradrenergic and serotonergic compounds were overall reduced in DS+AD versus EOAD, while the dopaminergic system showed a bidirectional change. For DS versus non-DS controls, significantly decreased MHPG levels were noted in various brain regions, though to a lesser extent than for DS+AD versus EOAD. Apart from DOPAC, CSF/plasma concentrations were not altered between groups. Monoamine neurotransmitters and metabolites were evidently impacted in DS, DS+AD, and EOAD. DS and DS+AD presented a remarkably similar monoaminergic profile, possibly related to early deposition of amyloid pathology in DS. To confirm whether monoaminergic alterations are indeed due to early amyloid β accumulation, future avenues include positron emission tomography studies of monoaminergic neurotransmission in relation to amyloid deposition, as well as relating monoaminergic concentrations to CSF/plasma levels of amyloid β and tau within individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers

  • van Waalwijk van Doorn, Linda J. C.
  • Ghafoorian, Mohsen
  • van Leijsen, Esther M. C.
  • Claassen, Jurgen A. H. R.
  • Arighi, Andrea|||0000-0003-2865-3970
  • Bozzali, Marco
  • Cannas, Jorge
  • Cavedo, Enrica|||0000-0003-2306-0164
  • Eusebi, Paolo
  • Farotti, Lucia
  • Fenoglio, Chiara|||0000-0001-6332-4721
  • Fortea, Juan|||0000-0002-1340-638X
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Greco, Viviana
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Liu, Yawu
  • Lleó, Alberto|||0000-0002-2568-5478
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Nobili, Flavio M.
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Picco, Agnese
  • Pikkarainen, Maria
  • Salvadori, Nicola
  • Scarpini, Elio|||0000-0002-6395-2119
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tarducci, Roberto
  • Urbani, Andrea
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Meulenbroek, Olga
  • Platel, Bram
  • Verbeek, Marcel M.
  • Kuiperij, H. Bea
The cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ), total and phosphorylated tau (t-tau, p-tau) are increasingly used to assist in the clinical diagnosis of Alzheimer's disease (AD). However, CSF biomarker levels can be affected by confounding factors. To investigate the association of white matter hyperintensities (WMHs) present in the brain with AD CSF biomarker levels. We included CSF biomarker and magnetic resonance imaging (MRI) data of 172 subjects (52 controls, 72 mild cognitive impairment (MCI), and 48 AD patients) from 9 European Memory Clinics. A computer aided detection system for standardized automated segmentation of WMHs was used on MRI scans to determine WMH volumes. Association of WMH volume with AD CSF biomarkers was determined using linear regression analysis. A small, negative association of CSF Aβ, but not p -tau and t -tau, levels with WMH volume was observed in the AD (r 2 = 0.084, p = 0.046), but not the MCI and control groups, which was slightly increased when including the distance of WMHs to the ventricles in the analysis (r 2 = 0.105, p = 0.025). Three global patterns of WMH distribution, either with 1) a low, 2) a peak close to the ventricles, or 3) a high, broadly-distributed WMH volume could be observed in brains of subjects in each diagnostic group. Despite an association of WMH volume with CSF Aβ levels in AD patients, the occurrence of WMHs is not accompanied by excess release of cellular proteins in the CSF, suggesting that WMHs are no major confounder for AD CSF biomarker assessment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species

  • Oliveira, Francisco
  • Leuzy, Antoine
  • Castelhano, Joäo
  • Chiotis, Konstantinos|||0000-0002-5679-0297
  • Hasselbalch, Steen Gregers
  • Rinne, Juha
  • Mendonça, Alexandre
  • Otto, Markus
  • Lleó, Alberto|||0000-0002-2568-5478
  • Santana, Isabel|||0000-0002-8114-9434
  • Johansson, Jarkko
  • Anderl-Straub, Sarah
  • Arnim, Christine
  • Beer, Ambros
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Portelius, Erik
  • Pannee, Josef
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Moreira, Ana P.
  • Abrunhosa, Antero
  • Nordberg, Agneta|||0000-0001-7345-5151
  • Castelo-Branco, Miguel|||0000-0003-4364-6373
Positron emission tomography (PET) neuroimaging with the Pittsburgh Compound_B (PiB) is widely used to assess amyloid plaque burden. Standard quantification approaches normalize PiB-PET by mean cerebellar gray matter uptake. Previous studies suggested similar pons and white-matter uptake in Alzheimer's disease (AD) and healthy controls (HC), but lack exhaustive comparison of normalization across the three regions, with data-driven diagnostic classification. We aimed to compare the impact of distinct reference regions in normalization, measured by data-driven statistical analysis, and correlation with cerebrospinal fluid (CSF) amyloid β (Aβ) species concentrations. 243 individuals with clinical diagnosis of AD, HC, mild cognitive impairment (MCI) and other dementias, from the Biomarkers for Alzheimer's/Parkinson's Disease (BIOMARKAPD) initiative were included. PiB-PET images and CSF concentrations of Aβ, Aβ and Aβ were submitted to classification using support vector machines. Voxel-wise group differences and correlations between normalized PiB-PET images and CSF Aβ concentrations were calculated. Normalization by cerebellar gray matter and pons yielded identical classification accuracy of AD (accuracy-96%, sensitivity-96%, specificity-95%), and significantly higher than Aβ concentrations (best accuracy 91%). Normalization by the white-matter showed decreased extent of statistically significant multivoxel patterns and was the only method not outperforming CSF biomarkers, suggesting statistical inferiority. Aβ and Aβ correlated negatively with PiB-PET images normalized by the white-matter, corroborating previous observations of correlations with non-AD-specific subcortical changes in white-matter. In general, when using the pons as reference region, higher voxel-wise group differences and stronger correlation with Aβ, the Aβ/Aβ or Aβ/Aβ ratios were found compared to normalization based on cerebellar gray matter.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

C-Terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease

  • García-Ayllón, María-Salud
  • Lopez-Font, Inmaculada
  • Boix, Claudia P.
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
This study assesses whether C-Terminal fragments (CTF) of the amyloid precursor protein (APP) are present in cerebrospinal fluid (CSF) and their potential as biomarkers for Alzheimer's disease (AD). Immunoprecipitation and simultaneous assay by Western blotting using multiplex fluorescence imaging with specific antibodies against particular domains served to characterize CTFs of APP in human CSF. We demonstrate that APP-CTFs are detectable in human CSF, being the most abundant a 25-kDa fragment, probably resulting from proteolytic processing by •-secretase. The level of the 25-kDa APP-CTF was evaluated in three independent CSF sample sets of patients and controls. The CSF level of this 25-kDa CTF is higher in subjects with autosomal dominant AD linked to PSEN1 mutations, in demented Down syndrome individuals and in sporadic AD subjects compared to age-matched controls. Our data suggest that APP-CTF could be a potential diagnostic biomarker for AD.